Single Nucleotide Polymorphism and Chemotherapy Response of Breast Cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

TANG Jinhai ¹ , ZHAO Jianhua ²

1.Department of General Surgery, Jiangsu Cancer Hospital, Nanjing 210009, China;;
2.Molecule Laboratory,Center of Clinical Laboratory Science of Jiangsu Province, Jiangsu Cancer Hospital, Nanjing 210009, China;

Corresponding author：

Keywords：

Polymorphism; Chemotherapy; Individualized treatment; Breast cancer

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the relationship between single nucleotide polymorphism (SNP) and therapy response of some conventional chemotherapy drugs in breast cancer, and to explore the value of SNP in guiding individualized treatment. Methods Pub-Medline and Chinese CHKD periodical electronic databases were searched. Representative researches in this field were sorted out and concluded. Results Varied genes related to drug metabolism have SNP phenomenon, which are closely associated with interindividual diversity in drug response. Race, section, environment, and drug-drug or gene-gene interactions may have effect on the association.Conclusion The study on SNP has important application prospect in optimizing the individual drug-delivery. However, the combinatorial analyses of multi-SNPs and multi-genes and the prospective studies with large-scale samples and random controls are still needed.

Citation： TANG Jinhai,ZHAO Jianhua. Single Nucleotide Polymorphism and Chemotherapy Response of Breast Cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2008, 15(12): 950-953. doi: Copy

1.	International HapMap Consortium. A haplotype map of the human genome [J]. Nature, 2005; 437(7063)∶ 1299.
2.	Giacomini KM, Brett CM, Altman RB, et al. The pharmacogenetics research network: from SNP discovery to clinical drug response [J]. Clin Pharmacol Ther， 2007; 81(3)∶ 328.
3.	Choi JY, Nowell SA, Blanco JG, et al. The role of genetic variability in drug metabolism pathways in breast cancer prognosis [J]. Pharmacogenomics, 2006; 7(4)∶ 613.
4.	Kim SJ, Noguchi S. Prediction of response to docetaxel in breast cancer [J]. Gan To Kagaku Ryoho, 2008; 35(2)∶ 190.
5.	Marsh S, Somlo G, Li X, et al. Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer [J]. Pharmacogenomics J， 2007; 7(5)∶362.
6.	Nakajima M, Fujiki Y, Kyo S, et al. Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1 [J]. J Clin Pharmacol, 2005; 45(6)∶ 674.
7.	范伟，杨金巧，伍晓汀. 乳腺浸润性导管癌中PS2和GSTπ的表达及临床意义 [J]. 中国普外基础与临床杂志， 2004; 11(1)∶14.
8.	Medeiros R, Pereira D, Afonso N, et al. Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome [J]. Int J Clin Oncol, 2003; 8(3)∶ 156.
9.	Sweeney C, McClure GY, Fares MY, et al. Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism [J]. Cancer Res, 2000; 60(20)∶5621.
10.	Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo [J]. Proc Natl Acad Sci USA, 2000; 97(7)∶ 3473.
11.	Bosch TM, Huitema AD, Doodeman VD, et al. Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel [J]. Clin Cancer Res, 2006; 12(19)∶ 5786.
12.	沈绍华，叶欣，顾龙君. 微管蛋白与多药耐药 [J]. 国际肿瘤学杂志， 2006; 33(2)∶104.
13.	Wiesen KW, Xia S, Yang CP, et al. Wild-type class Ⅰ beta-tubulin sensitizes Taxol-resistant breast adenocarcinoma cells harboring a beta-tubulin mutation [J]. Cancer Lett， 2007; 257(2)∶ 227.
14.	Hari M, Loganzo F, Annable T, et al. Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of β-tubulin (Asp26Glu) and less stable microtubules [J]. Mol Cancer Ther， 2006; 5(2)∶270.
15.	Maeno K, Ito K, Hama Y, et al. Mutation of the class Ⅰ beta-tubulin gene does not predict response to paclitaxel for breast cancer [J]. Cancer Lett， 2003; 198(1)∶ 89.
16.	Christine BA, Jiyoung A, Keshav KS, et al. Polymorphisms in genes related to oxidative stress (MPO, MnSOD, CAT) and survival after treatment for breast cancer[J]. Cancer Res, 2005; 65(3)∶1105.
17.	Ambrosone CB, Sweeney C, Coles BF, et al. Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer [J]. Cancer Res， 2001; 61(19)∶ 7130.
18.	Kafka A, Sauer G, Jaeger C, et al. Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer [J]. Int J Oncol, 2003; 22(5)∶ 1117.
19.	Honjo Y, Hrycyna CA, Yan QW, et al. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells [J]. Cancer Res, 2001; 61(18)∶ 6635.
20.	Concin N, Hofstetter G, Berger A, et al. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo [J]. Clin Cancer Res, 2005; 11(23)∶ 8372.
21.	Xu Y, Yao L, Ouyang T, et al. p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer [J]. Clin Cancer Res, 2005; 11(20)∶ 7328.
22.	Sullivan A， Syed N, Gasco M, et al. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo [J]. Oncogene, 2004; 23(19)∶ 3328.
23.	Xie HJ, Yasar U, Lundgren S, et al. Role of Polymorphic human CYP2B6 in cyclophosphamide bioactivation [J]. Pharmacogenomics J, 2003; 3 (1)∶ 53.
24.	Petros WP, Hopkins PJ, Spruill S, et al. Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer [J]. J Clin Oncol, 2005; 23(25)∶ 6117.
25.	Sweeney C, Ambrosone CB, Joseph L, et al. Association between a glutathione S-transferase A1 promoter polymorphism and survival after breast cancer treatment [J]. Int J Cancer, 2003; 103(6)∶810.
26.	Cai S, Ernstberger A, Wang H, et al. In vivo selection of hematopoietic stem cells transduced at a low multiplicity-of-infection with a foamy viral MGMT(P140K) vector [J]. Exp Hematol, 2008; 36(3)∶ 283.
27.	Pusztai L, Symmans FW, Hortobagyi GN. Development of pharmacogenomic markers to select preoperative chemotherapy for breast cancer [J]. Breast Cancer, 2005; 12(2)∶ 73.
28.	Bewick MA, Conlon MS, Lafrenie RM. Polymorphisms in manganese superoxide dismutase, myeloperoxidase and glutathione-S-transferase and survival after treatment for metastatic breast cancer [J]. Breast Cancer Res Treat, 2008; 11(1)∶ 93.
29.	Abecasis G, Tam PK, Bustamante CD, et al. Human Genome Variation 2006: emerging views on structural variation and large-scale SNP analysis [J]. Nat Genet, 2007; 39(2)∶153.

1. International HapMap Consortium. A haplotype map of the human genome [J]. Nature, 2005; 437(7063)∶ 1299.
2. Giacomini KM, Brett CM, Altman RB, et al. The pharmacogenetics research network: from SNP discovery to clinical drug response [J]. Clin Pharmacol Ther， 2007; 81(3)∶ 328.
3. Choi JY, Nowell SA, Blanco JG, et al. The role of genetic variability in drug metabolism pathways in breast cancer prognosis [J]. Pharmacogenomics, 2006; 7(4)∶ 613.
4. Kim SJ, Noguchi S. Prediction of response to docetaxel in breast cancer [J]. Gan To Kagaku Ryoho, 2008; 35(2)∶ 190.
5. Marsh S, Somlo G, Li X, et al. Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer [J]. Pharmacogenomics J， 2007; 7(5)∶362.
6. Nakajima M, Fujiki Y, Kyo S, et al. Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1 [J]. J Clin Pharmacol, 2005; 45(6)∶ 674.
7. 范伟，杨金巧，伍晓汀. 乳腺浸润性导管癌中PS2和GSTπ的表达及临床意义 [J]. 中国普外基础与临床杂志， 2004; 11(1)∶14.
8. Medeiros R, Pereira D, Afonso N, et al. Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome [J]. Int J Clin Oncol, 2003; 8(3)∶ 156.
9. Sweeney C, McClure GY, Fares MY, et al. Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism [J]. Cancer Res, 2000; 60(20)∶5621.
10. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo [J]. Proc Natl Acad Sci USA, 2000; 97(7)∶ 3473.
11. Bosch TM, Huitema AD, Doodeman VD, et al. Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel [J]. Clin Cancer Res, 2006; 12(19)∶ 5786.
12. 沈绍华，叶欣，顾龙君. 微管蛋白与多药耐药 [J]. 国际肿瘤学杂志， 2006; 33(2)∶104.
13. Wiesen KW, Xia S, Yang CP, et al. Wild-type class Ⅰ beta-tubulin sensitizes Taxol-resistant breast adenocarcinoma cells harboring a beta-tubulin mutation [J]. Cancer Lett， 2007; 257(2)∶ 227.
14. Hari M, Loganzo F, Annable T, et al. Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of β-tubulin (Asp26Glu) and less stable microtubules [J]. Mol Cancer Ther， 2006; 5(2)∶270.
15. Maeno K, Ito K, Hama Y, et al. Mutation of the class Ⅰ beta-tubulin gene does not predict response to paclitaxel for breast cancer [J]. Cancer Lett， 2003; 198(1)∶ 89.
16. Christine BA, Jiyoung A, Keshav KS, et al. Polymorphisms in genes related to oxidative stress (MPO, MnSOD, CAT) and survival after treatment for breast cancer[J]. Cancer Res, 2005; 65(3)∶1105.
17. Ambrosone CB, Sweeney C, Coles BF, et al. Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer [J]. Cancer Res， 2001; 61(19)∶ 7130.
18. Kafka A, Sauer G, Jaeger C, et al. Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer [J]. Int J Oncol, 2003; 22(5)∶ 1117.
19. Honjo Y, Hrycyna CA, Yan QW, et al. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells [J]. Cancer Res, 2001; 61(18)∶ 6635.
20. Concin N, Hofstetter G, Berger A, et al. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo [J]. Clin Cancer Res, 2005; 11(23)∶ 8372.
21. Xu Y, Yao L, Ouyang T, et al. p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer [J]. Clin Cancer Res, 2005; 11(20)∶ 7328.
22. Sullivan A， Syed N, Gasco M, et al. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo [J]. Oncogene, 2004; 23(19)∶ 3328.
23. Xie HJ, Yasar U, Lundgren S, et al. Role of Polymorphic human CYP2B6 in cyclophosphamide bioactivation [J]. Pharmacogenomics J, 2003; 3 (1)∶ 53.
24. Petros WP, Hopkins PJ, Spruill S, et al. Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer [J]. J Clin Oncol, 2005; 23(25)∶ 6117.
25. Sweeney C, Ambrosone CB, Joseph L, et al. Association between a glutathione S-transferase A1 promoter polymorphism and survival after breast cancer treatment [J]. Int J Cancer, 2003; 103(6)∶810.
26. Cai S, Ernstberger A, Wang H, et al. In vivo selection of hematopoietic stem cells transduced at a low multiplicity-of-infection with a foamy viral MGMT(P140K) vector [J]. Exp Hematol, 2008; 36(3)∶ 283.
27. Pusztai L, Symmans FW, Hortobagyi GN. Development of pharmacogenomic markers to select preoperative chemotherapy for breast cancer [J]. Breast Cancer, 2005; 12(2)∶ 73.
28. Bewick MA, Conlon MS, Lafrenie RM. Polymorphisms in manganese superoxide dismutase, myeloperoxidase and glutathione-S-transferase and survival after treatment for metastatic breast cancer [J]. Breast Cancer Res Treat, 2008; 11(1)∶ 93.
29. Abecasis G, Tam PK, Bustamante CD, et al. Human Genome Variation 2006: emerging views on structural variation and large-scale SNP analysis [J]. Nat Genet, 2007; 39(2)∶153.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Single Nucleotide Polymorphism and Chemotherapy Response of Breast Cancer

Abstract Full text Figures/Tables Video References Cited by

Format

Content